André Paternò Castello Dias Carneiro
@andrepcdc
GU Medical Oncologist at Hospital Israelita Albert Einstein (@hosp_einstein); LACOG member (@lacog_group); Tweets are my own.
Talvez você curta
49yo, female, sporadic/acquired FH deficient Papillary Renal Cell Carcinoma with bone-only recurrence 10m after nefrectomy. Only 2 mets, but symptomatic (pain) and growing towards the brain. Radioresistant…
Finally IO/IO emerging as an option for fav risk disease! Selection is key and an unmet need (biomarkers), but not considering this strategy deprive some fav risk pts of having long term benefits.
Renal cell carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment, and follow-up! @myESMO @tompowles1 @AlbigesL @ViktorGruenwald @ravikanesvaran @DrRanaMcKay @g_procopio_ @Silke_Gillessen @crisuarez08 @jteoh_hk @g_develasco @OncoAlert @kidneycan @KidneyCancer…
Great honor to be part of this important paper around mUC and the role of IO combos in 1L. Thanks @fsabino_onco for the leadership. Amazing!!
⚡️Just out at @CHematology the 1st systematic review and NMA with immune-combos in 1st line mUC (including the data of EV-302 just published). sciencedirect.com/science/articl… @SoaresAndrey @fmassari79 @vmollica7 @BourlonMaite @shilpaonc @asasse @andrepcdc
As ADCs come into play and precision medicine evolves, it becomes more important to improve patient selection for therapies in aUC. Great study on the expression of TROP2 and NECTIN-4, by @Markuseckstein3 and colleagues. Maybe ADCs are not for everyone. onlinelibrary.wiley.com/doi/10.1111/hi…
Very nice discussion today around papillary renal cell carcinoma with the @cityofhope dream team represented by the amazing @montypal. Congrats @glaucia_asc for the presentation 🇧🇷🇺🇸
“Why It Takes Forever to Get a Doctor's Appointment | Time”. What a great summary of the endless storm we face daily. By @ilanayurkiewicz time.com/6313270/doctor…
time.com
Why It Takes Forever to Get a Doctor's Appointment
Doctors are working harder and longer, all while patients can access them less.
There is recently a consistency of data showing that treatment intensification improves PFS in this high-risk BCR subset of pts. I just wonder at what expense.. will OS improve as well? Or are we just adding toxicities to delay relapse? 👀
Abs#5016 #ASCO23 @ASCO: STARTAR Ph II trial of ADT, apalutamide, salvage RT, and 6 cycles of docetaxel for high-risk BCR post-RP. Impressive 3-yr PFS 72% ➡️ Eagerly await results of similar Ph 3 #prostatecancer trials ENZARAD, ATLAS, PROTEUS, DASL-HiCaP
Enzalutamide finds a home in earlier stage disease, decreasing the risk of metastasis in about 60% for those with high risk biochemical recurrence.
Conclusions from EMBARK at AUA 2023!
FDA pours cold water on approval of Lymparza for all-comers. After approval in Europe (EMA) and in 🇧🇷 (ANVISA), FDA argues it only works in a subset of patients and that for those without BRCAm there’s only a “modest benefit” and even “possible harm.” fiercepharma.com/pharma/fda-arg…
fiercepharma.com
FDA argues AstraZeneca, Merck's Lynparza only works in subset of prostate cancer patients
AstraZeneca and Merck & Co.’s Lynparza may have claimed a broad trial success—and European approval—in prostate cancer, but the FDA has its reservations. | AstraZeneca and Merck & Co.’s Lynparza may...
Amazing news in mCSPC. While new treatments are welcome, patient selection is an unmet need. MutSPOP was associated w/ ⬇️80% risk in both time to CRPC and OS for ARPIs treatment, but not Docetaxel. Kudos for the paper and great discussion @umangtalking @nsayeghmd @ggebraelmd
SPOP mutations are the first predictive biomarker for treatment selection in de novo mHSPC; @ggebraelmd, @nsayeghmd & @umangtalking discuss the implications: fal.cn/3wFvv #pcsm #ASCODailyNews
As a matter of fact, from an oncologic perspective at least, there is no such thing as a maximum secure amount of alcohol consumption…
Alcohol🍷consumption increases the risk of #Cancer Be mindful of your intake and prioritize your health❤️🩹 @OncoAlert 🚨 #AlcoholAndCancer #WeCare #PrEvCan
Now I’m worried 🤔
A meta-epidemiological study found that meta-analyses of the same trials may obtain drastically conflicting results - ScienceDirect sciencedirect.com/science/articl…
Em 1o lugar e buscando mais! Orgulho enorme por fazer parte desse time e acompanhar de perto o crescimento exponencial da oncologia do @hosp_einstein! 1st and seeking more! Huge pride for being part of this team and closely follow Einstein’s exponential growth
Today, @hosp_einstein announced plans for a transformational cancer center, which will significantly advance our oncology department - currently ranked #1 in Latin America and #16 worldwide (@Newsweek). Estimated investment of 250 million dollars. www1.folha.uol.com.br/equilibrioesau…
folha.uol.com.br
Einstein anuncia novo centro oncológico de R$ 1,2 bilhão - 06/12/2022 - Equilíbrio e Saúde - Folha
Empreendimento será erguido em bairro planejado na marginal Pinheiros e pretende figurar entre os dez melhores do mundo
JUST IN: Phase 3 KEYNOTE-921 Trial Evaluating pembrolizumab+docetaxel vs docetaxel alone in Metastatic Castration-Resistant Prostate Cancer (CRPC) did not meet primary endpoints of OS and rPFS @DanaFarber_GU @OncoAlert @Merck @PCFnews merck.com/news/merck-pro…
merck.com
Merck Provides Update on Phase 3 KEYNOTE-921 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus...
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the Phase 3 KEYNOTE-921 trial evaluating KEYTRUDA in combination with chemotherapy (docetaxel) compared to...
Com o objetivo de promover uma revisão do conteúdo relevante em oncologia do último ano, a 13ª edição do Board Review in Medical Oncology, promovido pelo @hosp_einstein, acontece entre os dias 03 e 06 de agosto, em formato híbrido - tinyurl.com/rcwt5hj5
60y/o male, otherwise healthy, mildly symptomatic due to an unresectable recurrence of a ccRCC (lung, bones) during adjuvant Pembro. What’d be your 1L? @ShaanDudani @ChunLGan @SoaresAndrey @fsabino_onco @AlineHada @Ro_Mariano85 @DanielVargas_ @DrAndreFay @DiogoAssed
United States Tendências
- 1. Thanksgiving 417K posts
- 2. National Guard 47.3K posts
- 3. #InfoSecVPN N/A
- 4. Bayern 156K posts
- 5. Mbappe 73.4K posts
- 6. Arsenal 285K posts
- 7. Kimmich 4,038 posts
- 8. Denzel 4,031 posts
- 9. Golesh 2,974 posts
- 10. Olympiacos 17.2K posts
- 11. Lennart Karl 3,050 posts
- 12. Camp Haven 7,613 posts
- 13. Wine 40.4K posts
- 14. Pizza 48.7K posts
- 15. Fani Willis 21.6K posts
- 16. #ARSBAY 3,528 posts
- 17. Anthony Rendon N/A
- 18. #WipersDayGiveaway N/A
- 19. Neuer 5,811 posts
- 20. NextNRG Inc 1,498 posts
Talvez você curta
-
Denis Jardim
@jardim_denis -
Guilherme Nader Marta
@GuiNaderMarta -
Rodrigo Coutinho Mariano
@Ro_Mariano85 -
Veridiana Pires De Camargo
@pires_veridiana -
Fernando Sabino, MD, PhD
@fsabino_onco -
Paulo Amaral, MD
@paulosiqamaral -
Daniel Vargas Pivato de Almeida
@drdanielvargas -
Rafael H. Santos Abduch
@rafaelabduch -
Felippe Lazar
@felippelazar -
Diego Holanda
@cdiegoholanda -
Thais Megid
@MegidThais -
Mariana
@mcgouveia_
Something went wrong.
Something went wrong.